[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-the-prostate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-the-prostate":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,60,96,125,153,180,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100595161","phase-3-this-study-will-explore-whether-a-combination-of-the-investigational-drug-mevrometostat-pf-06821497-and-enzalutamide-will-work-better-than-taking-enzalutamide-alone-in-participants-with-mcspc-who-are-arpi-nave-100595161",false,"NCT07028853","This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)","Inclusion Criteria\n\n* Male participants aged ≥18 years (or the minimum age of consent in accordance with local regulations) at screening.\n* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.\n* Metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesion(s) on CT or MRI (for soft tissue\u002Fvisceral disease).\n* Resolution of acute effects of any prior therapy to either baseline severity or CTCAE Grade ≤1 (except for AEs which do not constitute a safety risk in the investigator's judgement).\n* Participants must have ECOG PS 0 or 1.\n\nExclusion Criteria\n\n* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation\u002Fbehavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* Clinically significant cardiovascular disease.\n* Known or suspected brain metastasis or active leptomeningeal disease.\n* Participants must be treatment naïve at the mCSPC stage, eg, participants cannot have received any cytotoxic chemotherapy with the following exceptions: Treatment with first-generation antiandrogen (ADT) agents is allowed for mCSPC.\n* Previous administration with an investigational product (drug or vaccine) within 30 days.\n* Use of 5-alpha reductase inhibitors is prohibited within 28 days of randomization.\n* Prior surgery from which the participant has not fully recovered at least 28 days prior to randomization\n* Current use or anticipated need for drugs that are known strong CYP3A4\u002F5 inhibitors and inducers (with exception of enzalutamide as part of this study).\n* Inadequate organ function.\n* Known allergic or hypersensitivity reactions to mevrometostat or its excipients or to enzalutamide or its excipients.","MALE","18 Years",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.",[26,27,28,29],"Metastatic Castration Sensitive Prostate Cancer (mCSPC)","Hormone Sensitive Prostate Cancer","Prostate Cancer","Cancer of the Prostate",[27,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Mevrometostat","Metastatic castration sensitive prostate cancer","PF-06821497","EZH2","enhancer of zeste homologue-2","enzalutamide","mCSPC","HSPC","Prostate cancer","castrate sensitive prostate cancer","prostatecancer-study.com","Phase 3","efficacy","safety","pharmacokinetics","pharmacodynamics","RECRUITING","2026-06-26",{"date":50,"type":51},"2026-06-30","ACTUAL",{"date":53,"type":51},"2025-09-28",{"date":55,"type":20},"2034-12-08",{"name":57,"class":58},"Pfizer","INDUSTRY",341,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":67,"minAge":17,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100544006","a-smart-design-to-optimize-the-delivery-of-tempo-for-men-with-prostate-cancer-and-their-caregivers-100544006","NCT06363266","A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers","A SMART Design to Optimize the Delivery of TEMPO - a Tailored, wEb-based Psychosocial and Physical Activity Self-Management PrOgram for Men With Prostate Cancer and Their Caregivers","Patient inclusion criteria: Prostate cancer diagnosis; Treatment for prostate cancer (excluding active surveillance) scheduled to start or received within the past 2 years; Nominate a caregiver willing to participate; Report at least moderate anxiety (ESAS-r Anxiety 3+); Be able to read English or French; Have access to the internet\n\nCaregiver inclusion criteria: Are nominated by patient as primary support person; Are patients' spouse, partner, or other family member; If patient does not report moderate anxiety, caregiver needs to; Be able to read English or French; Have access to the internet\n\nExclusion criteria for patient and caregiver: Hospitalized","ALL",{"count":69,"type":20},376,[71],"NA","Men with prostate cancer and their family caregivers face many physical and emotional challenges from the cancer itself and its treatment(s), which often lead to high anxiety. The pandemic has highlighted the importance of protecting our physical and mental health, and the complex responsibilities that caregivers have in supporting their loved ones. To improve the health of men with prostate cancer and of their caregivers, the research team developed TEMPO: a self-directed Tailored, wEb-based, psychosocial and physical activity self-Management PrOgram. TEMPO was developed with men with prostate cancer and their caregivers over the past 8 years. It also combines the investigators' research conducted over the past decade on providing the best support to those affected by cancer. Because the cancer care workforce is already overstretched, the research team designed TEMPO to be used without guidance from a health care professional. TEMPO is one-of-a kind in its support of both patients and caregivers, and the integration of coping skills training on a wide range of cancer challenges along with a home-based exercise program. Patients and caregivers who have used TEMPO said they improved their communication, learned new skills to cope with both physical and emotional challenges of cancer, and increased their physical activity. The present project builds on this work to further evaluate the cost and impact of TEMPO on men's and caregivers' health. Men with prostate cancer and their caregivers will be assigned by chance to one of two groups a) TEMPO or b) monitor their anxiety for 12 weeks. After 12 weeks, patients' and caregivers' needing more support will be identified based on an assessment of their anxiety level. For those already using TEMPO and needing more support, non-health care professional guidance might be offered. All those in the monitoring group needing more support will now have access to TEMPO. All participants complete surveys to determine whether TEMPO led to improved health outcomes.",[29,74],"Anxiety",[76,77,78,79,80,81,82,83,84],"Behavior Change","Caregivers","Coping","E-Health","Illness Self-Management","Physical Activity","Psychosocial Oncology","Self-Directed Interventions","Web-Based Interventions","2026-06-08",{"date":87,"type":51},"2026-06-11",{"date":89,"type":51},"2025-08-01",{"date":91,"type":20},"2028-08-31",{"name":93,"class":94},"St. Mary's Research Center, Canada","OTHER",2,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":67,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100599460","investigation-of-impact-of-ai-on-prostate-cancer-workflow-100599460","NCT07084779","Investigation of Impact of AI on Prostate Cancer Workflow","Inclusion Criteria:\n\n* Plan of care is to undergo a biopsy of the prostate after a pre-biopsy MRI\n* Age 55-80\n* Prostate-specific antigen (PSA) between 3-10 ng\u002FmL\n* No prior diagnosis or treatment of prostate cancer\n\nExclusion Criteria:\n\n* Pre-biopsy MRI is of low quality\n* PI-QUAL score of 1 using PI-QUAL version 2","55 Years","80 Years",{"count":105,"type":20},150,[71],"This study will enroll participants who are undergoing an MRI before a prostate biopsy due to suspected prostate cancer. The purpose of this study is to see if the use of Artificial Intelligence (AI) helps detect lesions on an MRI better than a radiologist not using AI. The AI Rad Companion (AIRC) Prostate MRI application is a software that uses measurements of the prostate and will be utilized in this study to help detect potential cancerous lesions. The AI software will assign the lesions a PI-RADS score, which is a way to measure the chance of the lesion being cancer.\n\nThere are two parts to this study. The first part involves comparing the interpretation of prostate MRI images by a radiologist alone, a radiologist aided by AI, and AI alone. A systematic biopsy will be completed per standard of care. The radiologist may opt to include up to 2 additional AI-identified targets to biopsy in addition to those biopsied for standard of care.\n\nThe second part of the study involves utilizing the MRI images from the first part of the study in addition to retrospective prostate MRI images. These de-identified images, along with Prostate Image Quality (PI-QUAL) scores, clinical data, and biopsy results will be sent to Siemens in order to aid in the development of methods to identify good or bad image quality in prostate MRI images.",[28,109,29,110],"Prostatic Neoplasm","Neoplasms, Prostate",[112,113,114],"Artificial Intelligence","Magnetic Resonance Imaging","Biopsy","2026-05-13",{"date":117,"type":51},"2026-05-15",{"date":119,"type":51},"2025-09-09",{"date":121,"type":20},"2026-11-30",{"name":123,"class":94},"Case Comprehensive Cancer Center",1,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":124},"100609995","low-count-quantitative-spect-for-men-treated-with-radium-223-100609995","NCT07221825","Low-Count Quantitative SPECT for Men Treated With Radium-223","Inclusion Criteria - Patients:\n\n* Histologically or cytologically confirmed castration-resistant prostate cancer with symptomatic bone metastases.\n* Minimum detectable skeletal lesion count of 3.\n* Eligible to receive Xofigo.\n* At least 18 years of age.\n* ECOG performance status ≤ 3.\n* Ability to understand and willingness to sign an IRB-approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria - Patients:\n\n* Predominant visceral metastatic disease.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n* Concurrent alternative radiopharmaceuticals\n* Inability to maintain stationary supine pose for 45-60 minutes\n\nEligibility Criteria - Physicians:\n\n* Medical Oncologist or Radiation Oncologist at Siteman Cancer Center.\n* Treating patients with prostate cancer.\n* Willing to complete Physician Questionnaire during participation.",{"count":132,"type":20},38,[71],"Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \\[223Ra\\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development.\n\nSingle-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.",[28,29],[39,137,138,139,140,141,142],"Bone metastasis","SPECT","Radiopharmaceutical therapies","Theranostics","Alpha-particle","Xofigo","NOT_YET_RECRUITING","2026-04-20",{"date":146,"type":51},"2026-04-23",{"date":148,"type":20},"2026-07-01",{"date":150,"type":20},"2028-07-31",{"name":152,"class":94},"Washington University School of Medicine",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":159,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":124},"100601356","impact-of-an-electronic-health-record-maintenance-alert-on-psa-screening-rates-in-a-10-hospital-integrated-health-system-100601356","NCT07109427","Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System","Eligibility Criteria:\n\n* Receive care within the BJC Health System\n* Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care)\n* Be male\n* Not have a history of prostate cancer\n* Meet one of the following risk criteria:\n\n  * High Risk for Prostate Cancer\n\n    * African American, between the ages of 40 and 75 (inclusive), or\n    * Family history of prostate, breast, ovarian, and\u002For pancreatic cancer, or\n    * Known familial germline mutation OR\n  * Average Risk for Prostate Cancer\n\n    * Between the ages of 50 and 75 (inclusive)",true,"40 Years","75 Years",{"count":163,"type":20},40000,[71],"\\- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care:\n\n* Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines.\n* Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices.\n* The goal is to reduce late-stage presentation without increasing overdiagnosis-ensuring that prostate cancer screening is both accessible and clinically effective.",[28,29],[168,169,170,171],"PSA Screening","Clinically Significant Prostate Cancer","African American men","Electronic Health Record","2025-08-12",{"date":174,"type":51},"2025-08-17",{"date":176,"type":51},"2025-08-11",{"date":178,"type":20},"2031-08-31",{"name":152,"class":94},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":188,"maxAge":4,"enrollmentInfo":189,"targetDuration":191,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":124},"100457794","mriultrasound-fusion-guided-laser-ablation-of-prostate-cancer-100457794","NCT05241236","MRI\u002FUltrasound Fusion Guided Laser Ablation of Prostate Cancer","Office Based MRI\u002FUltrasound Guided Prostate Cancer Ablation: Outcomes Registry","MRFLA","Inclusion Criteria:\n\n* Men between 50 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \\\u003C50% positive core rate by prostate lobe\n* Men older than 65 years of age with clinical diagnosis of prostate cancer \\\u003C50% positive core rate by prostate lobe\n* Absence of extra-capsular extension\n* Absence of seminal vesicle invasion\n* Absence of regional or distant metastatic disease\n* Multiparametric MRI of the prostate performed either before the biopsy or \\>10 weeks after prostate biopsy\n* Treated with Cryotherapy of the prostate\n* Treatment based on co-registration between MP-MRI and Prostate Ultrasound\n\nExclusion Criteria:\n\n* Prior treatment of prostate cancer in the form of surgery.\n* Performance status greater than 0 based on ECOG criteria\n* Mental status impairment","50 Years",{"count":190,"type":20},5000,"10 Years","OBSERVATIONAL","This serves as a registration trial. It aims to record short, intermediate, and long-term outcomes of patients treated with targeted laser ablation of biopsy confirmed prostate cancer. Outcomes will be categorized as: 1- Procedure Related, 2- Perioperative - Adverse Events that may occur within 90 days, 3-Oncologic: Recurrence of cancer in treatment area, de-novo tumors, conversion to radical surgery, radiation or cryoablation, emergence of metastasis, 4- Functional: Sexual and Urinary function following treatment",[195,29],"Neoplasms Prostate",[197,198,199,200,201,202,203,204,205,206,207,208],"Prostate","PSA","FUSION","Ultrasound","MRI","Cancer","Laser","Outcomes","Recurrence","QOL, Quality of Life","Urinary function","Sexual Function","2023-01-24",{"date":211,"type":51},"2023-01-26",{"date":213,"type":51},"2020-11-15",{"date":215,"type":20},"2038-11",{"name":217,"class":94},"Urological Research Network, LLC",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":226,"targetDuration":191,"studyType":192,"phases":4,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":124},"100238430","mriultrasound-fusion-guided-prostate-cryotherapy-100238430","NCT02381990","MRI\u002FUltrasound Fusion Guided Prostate Cryotherapy","Office Based MRI\u002FUltrasound Guided Prostate Cryotherapy: Outcomes Registry","FIPC","Inclusion Criteria:\n\n* Men between 55 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \\\u003C50% positive core rate by prostate lobe\n* Men older than 65 years of age with clinical diagnosis of prostate cancer \\\u003C50% positive core rate by prostate lobe\n* Absence of extra-capsular extension\n* Absence of seminal vesicle invasion\n* Absence of regional or distant metastatic disease\n* Multiparametric MRI of the prostate performed either before the biopsy or \\>10 weeks after prostate biopsy\n* Treated with Cryotherapy of the prostate\n* Treatment based on co-registration between MP-MRI and Prostate Ultrasound\n\nExclusion Criteria:\n\n* Prior treatment of prostate cancer in the form of surgery.\n* Performance status greater than 0 based on ECOG criteria\n* Mental status impairment",{"count":190,"type":20},"Registration of Prostate Cancer patients undergoing Prostate Cryotherapy guided by Mutiparametric-MRI (MP-MRI) highlighting biopsy confirmed regions. The primary outcome measure is 5 year oncological control. Secondary aim is lack of progression beyond the prostate gland. The aim of intervention is to eradicate prostate cancer disease in the treated area while imposing no or minimal deleterious effects in quality of life.",[195,29],[197,198,199,200,201,202,230,204,205,206,207,208],"Cryotherapy",{"date":211,"type":51},{"date":233,"type":51},"2013-08",{"date":235,"type":20},"2033-08",{"name":217,"class":94}]